{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:40:05Z","timestamp":1756309205513,"version":"3.44.0"},"reference-count":29,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2022,9,23]]},"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:p>A woman presented to medical oncology with almost 4 years of untreated, slowly progressing, triple negative metastatic breast cancer to the lung. About 15 years prior, she was diagnosed with invasive ductal carcinoma of the right breast with ipsilateral chest wall recurrence 6 years later. Comprehensive molecular profiling of a metastatic lesion detected a hotspot <jats:italic>ETV6-NTRK3<\/jats:italic> fusion, which was not present on circulating tumour DNA or molecular profile performed 4 years prior. A second look pathological examination demonstrated tumour characteristics consistent with secretory breast carcinoma. Identification of <jats:italic>ETV6\u00ad-NKRT3<\/jats:italic> fusion allowed for treatment with larotrectinib, a tyrosine kinase inhibitor specifically indicated for secretory breast carcinoma. After 3 months, she experienced a partial response.<\/jats:p>","DOI":"10.1136\/bcr-2022-251656","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T11:20:18Z","timestamp":1665573618000},"page":"e251656","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Metastatic triple negative breast cancer with NTRK gene fusion on tissue but not on ctDNA molecular profile"],"prefix":"10.1136","volume":"15","author":[{"given":"Nupur","family":"Singh","sequence":"first","affiliation":[{"name":"College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rishika","family":"Singh","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brennan","family":"Decker","sequence":"additional","affiliation":[{"name":"West Cancer Center and Research Institute, Memphis, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Robins","sequence":"additional","affiliation":[{"name":"West Cancer Center and Research Institute, Memphis, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Vidal","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA"},{"name":"West Cancer Center and Research Institute, Memphis, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,10,12]]},"reference":[{"doi-asserted-by":"publisher","key":"2025082708051021000_15.10.e251656.1","DOI":"10.1038\/s41379-018-0118-3"},{"doi-asserted-by":"publisher","key":"2025082708051021000_15.10.e251656.2","DOI":"10.1038\/s41571-018-0113-0"},{"key":"2025082708051021000_15.10.e251656.3","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40265-018-1044-x","article-title":"Larotrectinib: first global approval","volume":"79","author":"Scott","year":"2019","journal-title":"Drugs"},{"unstructured":"Lakhani SR . Who classification of tumours of the breast. Lyon: International Agency for Research on Cancer, 2012.","key":"2025082708051021000_15.10.e251656.4"},{"doi-asserted-by":"publisher","key":"2025082708051021000_15.10.e251656.5","DOI":"10.1093\/annonc\/mdz204"},{"key":"2025082708051021000_15.10.e251656.6","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/pin.13204","article-title":"NTRK gene fusions are detected in both secretory and non-secretory breast cancers","volume":"72","author":"Maund","year":"2022","journal-title":"Pathol Int"},{"key":"2025082708051021000_15.10.e251656.7","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/modpathol.2011.190","article-title":"Secretory breast carcinoma: a clinicopathological and immunophenotypic study of 15 cases with a review of the literature","volume":"25","author":"Li","year":"2012","journal-title":"Mod Pathol"},{"key":"2025082708051021000_15.10.e251656.8","doi-asserted-by":"crossref","first-page":"viii16","DOI":"10.1093\/annonc\/mdz384","article-title":"Identifying patients with NTRK fusion cancer","volume":"30","author":"Solomon","year":"2019","journal-title":"Annals of Oncology"},{"doi-asserted-by":"publisher","key":"2025082708051021000_15.10.e251656.9","DOI":"10.6004\/jnccn.2014.0008"},{"doi-asserted-by":"publisher","key":"2025082708051021000_15.10.e251656.10","DOI":"10.1158\/1078-0432.CCR-06-3045"},{"doi-asserted-by":"publisher","key":"2025082708051021000_15.10.e251656.11","DOI":"10.3816\/CBC.2009.n.005"},{"key":"2025082708051021000_15.10.e251656.12","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.e12580","article-title":"5 year overall survival of triple negative breast cancer: a single institution experience","volume":"34","author":"Skandan","year":"2016","journal-title":"JCO"},{"doi-asserted-by":"publisher","key":"2025082708051021000_15.10.e251656.13","DOI":"10.20892\/j.issn.2095-3941.2018.0035"},{"doi-asserted-by":"crossref","unstructured":"Joseph B , Jack M , Alan H , et al . Secretory carcinoma of the breast: an elusive presentation of this rare pathology. Int J Oncol Res 2017;1.doi:10.23937\/ijor-2017\/1710002","key":"2025082708051021000_15.10.e251656.14","DOI":"10.23937\/ijor-2017\/1710002"},{"doi-asserted-by":"publisher","key":"2025082708051021000_15.10.e251656.15","DOI":"10.1016\/j.breast.2012.02.013"},{"key":"2025082708051021000_15.10.e251656.16","doi-asserted-by":"crossref","DOI":"10.1136\/jcp.2003.015149","article-title":"Secretory carcinoma of the male breast","volume":"57","author":"Niveditha","year":"2004","journal-title":"J Clin Pathol"},{"doi-asserted-by":"publisher","key":"2025082708051021000_15.10.e251656.17","DOI":"10.1186\/1477-7819-2-17"},{"doi-asserted-by":"publisher","key":"2025082708051021000_15.10.e251656.18","DOI":"10.1186\/1477-7819-3-35"},{"doi-asserted-by":"crossref","unstructured":"Huntsman D , Sorensen PHB , C n . Expression of the ETV6-NTRK3 gene fusion in human secretory breast carcinoma. In: Handbook of immunohistochemistry and in situ hybridization of human carcinomas, 2002: 493\u2013503.","key":"2025082708051021000_15.10.e251656.19","DOI":"10.1016\/S1874-5784(04)80060-6"},{"doi-asserted-by":"publisher","key":"2025082708051021000_15.10.e251656.20","DOI":"10.1074\/jbc.M307388200"},{"doi-asserted-by":"publisher","key":"2025082708051021000_15.10.e251656.21","DOI":"10.1136\/esmoopen-2015-000023"},{"key":"2025082708051021000_15.10.e251656.22","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1182\/blood.2020006164","article-title":"Molecular basis of ETV6-mediated predisposition to childhood acute lymphoblastic leukemia","volume":"137","author":"Nishii","year":"2021","journal-title":"Blood"},{"doi-asserted-by":"publisher","key":"2025082708051021000_15.10.e251656.23","DOI":"10.1023\/A:1008387800525"},{"key":"2025082708051021000_15.10.e251656.24","doi-asserted-by":"crossref","first-page":"e2020227","DOI":"10.4322\/acr.2020.227","article-title":"Secretory carcinoma of the breast, commonly exhibits the features of low grade, triple negative breast carcinoma- a case report with updated review of literature","volume":"11","author":"Banerjee","year":"2021","journal-title":"Autops Case Rep"},{"unstructured":"NCCN . Guidelines for breast cancer invasive patients; 2022: 1\u2013114.","key":"2025082708051021000_15.10.e251656.25"},{"key":"2025082708051021000_15.10.e251656.26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/01.COT.0000771920.05025.b7","article-title":"Asco releases rapid guideline recommendation update for certain patients with hereditary breast cancer","volume":"43","year":"2021","journal-title":"Oncology Times"},{"doi-asserted-by":"publisher","key":"2025082708051021000_15.10.e251656.27","DOI":"10.1038\/s41576-021-00338-8"},{"doi-asserted-by":"crossref","unstructured":"Cocco E , Kulick A , Misale S , et al . Resistance to trk inhibition mediated by convergent MAP kinase pathway activation. Experimental and Molecular Therapeutics 2019.doi:10.1158\/1538-7445.am2019-lb-118","key":"2025082708051021000_15.10.e251656.28","DOI":"10.1158\/1538-7445.AM2019-LB-118"},{"doi-asserted-by":"publisher","key":"2025082708051021000_15.10.e251656.29","DOI":"10.1016\/S1535-6108(02)00184-8"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2022-251656","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:05:19Z","timestamp":1756307119000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2022-251656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,12]]},"published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1136\/bcr-2022-251656"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2022-251656","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}